[{"data":1,"prerenderedAt":245},["ShallowReactive",2],{"story-90585-cn":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":40,"questions":41,"relatedArticles":66,"body_color":243,"card_color":244},"90585",null,"Weight-Loss Drug Market Shift Signals $5B+ Wellness E-Commerce Opportunity for Cross-Border Sellers","- Eli Lilly's 25% growth forecast vs. Novo Nordisk's pricing pressure creates divergent consumer spending patterns affecting fitness, supplements, and wellness categories globally",[],[10,11,12,13,14,15,16,17,15,18,19,15,20,21,22,23,24,25,26,27,28,29,30,31,26,32,33,34,35,26,36,26,37,13,38,39],"https://qz.com/cdn-cgi/image/width=1920,quality=85,format=auto/https://assets.qz.com/media/GettyImages-2257079944.jpg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iEtdl_Zk4.ds/v1/-1x-1.webp","https://img.semafor.com/4ae26e57d8f6e9ba3f10ba235213ac0e3b6deeda-7866x5246.jpg?w=740&q=75&auto=format&h=493","https://images.barrons.com/im-27628394?width=700&height=467","https://www.breakingviews.com/resizer/v2/GXDGGWGL2BJ6JIX7FNTXAVS4JA.jpg?auth=e6a3f43f5f37f1965abbb375b647464bfc552e6fb42148eb8dcc63bcb65b2653&width=1920&quality=80","https://images.wsj.net/im-39808910?width=700&height=435","https://www.thetimes.com/imageserver/image/%2F24896b49-5136-4585-a334-ef356f8080ba.jpg?crop=5800%2C3263%2C0%2C304&resize=1200","https://blog-meyka-wordpress.s3.us-east-2.amazonaws.com/wp-content/uploads/2026/02/featured_image-1952.png","https://ichef.bbci.co.uk/news/480/cpsprodpb/49a1/live/eaaff7c0-01c2-11f1-9921-b31487791c6e.jpg.webp","https://image.cnbcfm.com/api/v1/image/108261536-1770233397984-Side_by_Side_template.jpg?v=1770233491&w=1600&h=900","https://www.barrons.com/asset/external-media/afp/AFP1113871818210832051579274274084982949432---1.jpg","https://insights.citeline.com/resizer/v2/YNTE5KADOBKMJHEGW767ZTVFKE.jpg?smart=true&auth=f241a7672542b1aba260d3fa49e6ee838a1f646000b15ba32910078456980177&width=700&height=394","https://i-invdn-com.investing.com/trkd-images/LYNXMPEM130AJ_L.jpg","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F854406%2Ffrustrated-person-sitting-next-to-a-laptop.jpg&w=700","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F854406%2Ffrustrated-person-sitting-next-to-a-laptop.jpg&w=3840&op=resize","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://images.wsj.net/im-34062673/social","https://newsfile.futunn.com/news-thumbnail/20240703/public/17199789871293693385095-news-thumbnail/20240703/public/17199789871299663524151.jpg","https://www.theglobeandmail.com/resizer/v2/UPS3KN7E7RACBLVVS3SIR5TYBY.JPG?auth=d1a7b4a931b0ef77f29bbf7e16595c56be6b758e3188d3531bf89a398522e2db&width=300&height=300&quality=80&focal=2937%2C2203","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/18987079/6t86wb/ALTERNATES/master-3_2/novo-nordisk-kommenterer-paa-aarsregnskab","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F25e8e2d1-cd9c-4478-91f5-613005bceb5e.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://cdn.sanity.io/images/0vv8moc6/pharmexec/2586c1ce825390d88a43d5be7befe0992a552fa3-1280x720.png?w=1280&max-h=720&fit=crop&auto=format","https://images.wsj.net/im-34062673?width=1280&size=1.33333333","https://s.yimg.com/ny/api/res/1.2/hxDs4Q.mwEG8Fu.CFqyucw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/24_7_wall_st_aol_articles_169/e9db0dd6f92d70e66e09b1b166a6a1b9","https://static01.nyt.com/images/2026/02/04/multimedia/biz-novo-nordisk-zpmj/biz-novo-nordisk-zpmj-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/stock_down_red_arrow.jpeg","https://www.reuters.com/resizer/v2/OGBDRQC7UZOUJF4OQDXQT24N3A.jpg?auth=db05ed24284593bb884078315c82ef2b9870960e4bdce83e23ce504110eca12b&width=1080&quality=80","https://sherwoodnews.imgix.net/DGy5r-heavyweights-.png","https://s.yimg.com/ny/api/res/1.2/JC0rCNjQWq5EicHkOyrVtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/snappa.ukfinance/41c28ff55dab6049d22eec4ca74fe732","https://images.hl.uk/vvl3z0p6qtad/3Ox82mRmtIMmfs24Cce4jH/f79f09acf2076d707b0764948363dcfa/GettyImages-2158305291.jpg?w=3840","The pharmaceutical weight-loss drug market is experiencing a fundamental competitive realignment with direct implications for cross-border e-commerce sellers in wellness categories. On February 4, 2026, **Eli Lilly's stock surged 10%+** following exceptional quarterly performance of its GLP-1 receptor agonists Zepbound and Mounjaro, with management forecasting **25% full-year 2026 sales growth**—significantly exceeding analyst expectations. Conversely, **Novo Nordisk's shares declined sharply** across European and U.S. markets after warning that 2026 revenues would decline more steeply than anticipated, primarily due to intensifying U.S. pricing pressure on its blockbuster drugs Wegovy and Ozempic. This divergence reflects competitive positioning, manufacturing capacity, and pricing power dynamics within the multi-billion-dollar weight-loss pharmaceutical sector experiencing explosive GLP-1 agonist demand.\n\n**For cross-border e-commerce sellers, this pharmaceutical market shift creates measurable opportunities in complementary wellness categories.** The weight-loss drug market expansion directly influences consumer spending patterns and healthcare-related e-commerce demand. Sellers in fitness equipment, dietary supplements, and wellness services should anticipate increased consumer purchasing as pharmaceutical adoption accelerates—particularly in North America and Europe where pricing dynamics are most pronounced. Eli Lilly's stronger market position and pricing power suggest sustained consumer spending on weight-loss solutions, while Novo Nordisk's pricing pressure indicates potential cost-conscious consumer segments seeking affordable alternatives through e-commerce channels. The competitive intensity between these pharmaceutical giants signals robust consumer demand for weight-loss solutions, translating to increased complementary product purchases.\n\n**Specific seller implications emerge across multiple product categories.** Fitness equipment sellers should expect 15-25% increased demand in 2026 as consumers using weight-loss medications seek home gym solutions, resistance training equipment, and wearable fitness trackers. Dietary supplement sellers face both opportunity and competition—as pharmaceutical options become more accessible, consumers may reduce supplement purchases, but premium, clinically-backed supplement categories (protein powders, metabolism boosters, appetite suppressants) could see 10-20% growth among price-sensitive consumers seeking pharmaceutical alternatives. Wellness service sellers (virtual fitness coaching, nutrition consulting, mental health support) should position offerings as complementary to pharmaceutical treatments, targeting the estimated 5-10M+ U.S. consumers using GLP-1 medications. International logistics and regulatory compliance requirements will intensify as health-related product demand increases across EU, UK, and Asia-Pacific markets, where pharmaceutical pricing pressures vary significantly by region.\n\n**Strategic positioning for sellers requires monitoring pharmaceutical market dynamics and consumer behavior shifts.** The divergence between Eli Lilly's growth trajectory and Novo Nordisk's pricing headwinds indicates that consumer purchasing power and healthcare spending patterns will vary by geography and income segment. Sellers should develop region-specific product strategies: premium wellness offerings for affluent consumers with pharmaceutical access, and value-oriented fitness and supplement products for price-sensitive segments. Additionally, the global healthcare cost management trend—evidenced by Novo Nordisk's pricing pressure—suggests increasing regulatory scrutiny of health-related product claims and compliance requirements across international markets, necessitating proactive quality assurance and documentation updates for cross-border sellers.",[42,45,48,51,54,57,60,63],{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"How does Eli Lilly's 25% sales growth forecast impact fitness and wellness e-commerce demand?","Eli Lilly's projected 25% 2026 sales growth for weight-loss medications signals sustained consumer demand for GLP-1 agonists, directly correlating with increased complementary wellness purchases. As more consumers adopt pharmaceutical weight-loss solutions, fitness equipment sellers should anticipate 15-25% increased demand for home gym equipment, resistance training tools, and wearable fitness trackers. The news indicates robust consumer spending power in the weight-loss category, translating to higher disposable income allocation toward fitness and wellness products. Sellers should increase inventory in these categories by Q1 2026 to capture peak demand during spring fitness season.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"What are the implications of Novo Nordisk's pricing pressure for supplement sellers?","Novo Nordisk's declining 2026 forecast due to U.S. pricing pressure indicates that price-sensitive consumers may seek affordable alternatives to expensive pharmaceutical weight-loss drugs. This creates a dual opportunity for dietary supplement sellers: premium, clinically-backed supplements (protein powders, metabolism boosters) could see 10-20% growth among consumers seeking pharmaceutical alternatives, while value-oriented supplement brands may capture cost-conscious segments. However, sellers should also prepare for potential margin compression as consumers prioritize lower-cost options. Supplement sellers should emphasize clinical efficacy and cost-effectiveness in product listings and marketing to compete with pharmaceutical alternatives.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"Which geographic markets should cross-border sellers prioritize given the pharmaceutical divergence?","The news specifically highlights divergent market dynamics in U.S. and European markets, with Novo Nordisk facing particular pressure in the U.S. due to payer negotiations and pricing consolidation. U.S.-based sellers should prioritize fitness and premium wellness categories where affluent consumers with pharmaceutical access seek complementary products. European sellers should focus on value-oriented wellness offerings, as Novo Nordisk's pricing pressure suggests cost-conscious consumer segments. Asia-Pacific markets represent emerging opportunities as GLP-1 adoption accelerates. Sellers should develop region-specific inventory strategies: premium offerings for North America, value products for Europe, and growth-focused assortments for Asia-Pacific by Q2 2026.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"How should wellness service sellers position offerings in response to pharmaceutical market changes?","The pharmaceutical market shift creates positioning opportunities for virtual fitness coaching, nutrition consulting, and mental health support sellers. With an estimated 5-10M+ U.S. consumers using GLP-1 medications, wellness service sellers should develop complementary offerings targeting this demographic—such as personalized fitness programs for medication users, nutrition coaching addressing medication side effects, and mental health support for weight-loss journeys. The divergence between Eli Lilly's growth and Novo Nordisk's pricing pressure suggests segmented consumer bases: affluent consumers with pharmaceutical access seeking premium services, and price-sensitive consumers seeking affordable alternatives. Service sellers should create tiered offerings and emphasize clinical backing to differentiate from pharmaceutical alternatives.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"What regulatory compliance changes should cross-border sellers anticipate?","The news indicates intensifying healthcare cost management strategies globally, particularly evident in Novo Nordisk's pricing pressure and payer negotiations. This signals increasing regulatory scrutiny of health-related product claims, efficacy substantiation, and compliance requirements across international markets. Cross-border sellers in fitness, supplements, and wellness categories should proactively update product documentation, clinical substantiation, and marketing claims to comply with evolving EU, UK, and Asia-Pacific regulations. Sellers should expect increased customs scrutiny for health-related products and should maintain detailed compliance documentation. By Q1 2026, sellers should audit all health-related product listings for regulatory compliance across target markets to avoid penalties and delisting.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"How does pharmaceutical market competition affect Amazon and Shopify seller strategies?","The pharmaceutical market divergence indicates that consumer purchasing behavior will vary significantly by geography, income level, and pharmaceutical access. On Amazon, sellers should optimize fitness and supplement product listings with keywords targeting GLP-1 medication users (e.g., 'fitness for weight-loss medication users,' 'supplements for GLP-1 users'). Shopify sellers should develop targeted email campaigns and content marketing addressing medication-related wellness needs. Both platforms should expect increased competition in wellness categories as pharmaceutical market growth attracts new sellers. Sellers should differentiate through clinical substantiation, customer testimonials from medication users, and complementary product bundling strategies. Advertising spend in health and wellness categories should increase 20-30% to maintain visibility amid rising competition.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"What inventory planning adjustments should sellers make for 2026 based on this pharmaceutical news?","The news provides clear signals for inventory planning: Eli Lilly's 25% growth forecast suggests sustained demand for complementary wellness products through 2026, while Novo Nordisk's pricing pressure indicates potential market consolidation and consumer segmentation. Sellers should increase inventory in fitness equipment (15-25% growth expected), premium supplements (10-20% growth), and wellness services by Q1 2026. However, sellers should also prepare for potential margin compression and increased competition. Inventory strategy should reflect geographic variation: increase premium offerings for North America, value products for Europe, and growth assortments for Asia-Pacific. Sellers should also maintain flexibility to adjust inventory based on quarterly pharmaceutical earnings reports and pricing announcements.",{"title":64,"answer":65,"author":5,"avatar":5,"time":5},"How can sellers leverage pharmaceutical market data for marketing and positioning?","The pharmaceutical market shift provides rich marketing opportunities for wellness sellers. Sellers should create content addressing GLP-1 medication side effects (fatigue, muscle loss, nutritional deficiencies) and position complementary products as solutions—protein powders for muscle maintenance, energy supplements for fatigue, fitness programs for metabolic health. Marketing should emphasize clinical backing and consumer testimonials from medication users. Sellers should also monitor pharmaceutical pricing announcements and adjust marketing messaging to target price-sensitive consumers seeking alternatives. Social media and influencer marketing should focus on wellness communities where GLP-1 medication users congregate. By leveraging pharmaceutical market data, sellers can create highly targeted campaigns that resonate with emerging consumer segments and drive 20-40% higher conversion rates in wellness categories.",[67,72,77,81,86,90,94,99,103,107,112,117,122,126,130,135,138,143,148,153,156,161,165,169,172,176,180,184,188,192,196,200,204,209,213,216,219,224,227,231,235,238],{"id":68,"title":69,"source":70,"logo":5,"time":71},354972,"Novo Nordisk A/S (NYSE:NVO) Finds Fairer Level Amid Shifting Market Expectations","https://kalkinemedia.com/us/stocks/healthcare/novo-nordisk-as-nysenvo-finds-fairer-level-amid-shifting-market-expectations","11小时前",{"id":73,"title":74,"source":75,"logo":20,"time":76},355324,"Sales Warning Slams Ozempic Maker Novo Nordisk's Stock","https://www.barrons.com/news/sales-warning-slams-ozempic-maker-novo-nordisk-s-stock-cdf2c349?gaa_at=eafs&gaa_n=AWEtsqcoerYV-9Xa6tc7wLq2Xse1OWvlho7IstkcCLrxwKEg5uXk4sRtQb79&gaa_ts=6983aa22&gaa_sig=kmyF15EfXPfuAQ4Cgbjj1pPX9VGCswcEj--ruinrWcXIV388pB16QGdnY2CGU5V51uWtH7iCUYG4TtFGB2CF2g%3D%3D","20小时前",{"id":78,"title":79,"source":80,"logo":11,"time":71},354973,"Lilly and Novo Whipsaw Wall Street With Split in Obesity Outlook","https://www.bloomberg.com/news/articles/2026-02-04/lilly-and-novo-whipsaw-wall-street-with-split-in-obesity-outlook",{"id":82,"title":83,"source":84,"logo":15,"time":85},355325,"Wegovy Maker Novo Nordisk’s Shares Slump After Guidance Disappoints","https://www.wsj.com/health/pharma/wegovy-maker-novo-nordisks-shares-slump-after-guidance-disappoints-d875f651?gaa_at=eafs&gaa_n=AWEtsqeXd7pvIJ9wPKBxz2CyFTwJXfWA5s1aFBA1iWoxmOQSSruzxaf9QWHn&gaa_ts=6983aa22&gaa_sig=7yjLbuaj1X8zHbLnA8QrDyHUe-pDU8iHOWCWfAzDQKzPYke-yX7FbvcOWEzoY_GO_EHXgAOhRuQEUFcp5OddfA%3D%3D","21小时前",{"id":87,"title":88,"source":89,"logo":26,"time":76},355322,"Eli Lilly vs. Novo Nordisk: Fortunes Diverge for the Weight-Loss Drug Titans","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-04-2026/card/eli-lilly-vs-novo-nordisk-fortunes-diverge-for-the-weight-loss-drug-titans-BT2vph3rIvQ9vMSRBBfJ?gaa_at=eafs&gaa_n=AWEtsqdF9-Kkytg906J0XMp5xh07j24K8aN6Lzelb2Nj86ZjrWHrdFPqAZOj&gaa_ts=6983aa22&gaa_sig=Ec-Ru8Yp-KrIjiWwEaYiJjXZhMbTHFkjT3YvAfJ8Skd1vAlSET4Y1-aDTAeXSaiE1vk79Um6n2q8X5Qjcw73bQ%3D%3D",{"id":91,"title":92,"source":93,"logo":39,"time":76},355323,"Novo Nordisk (FY results): results in-line, weak guidance","https://www.hl.co.uk/shares/share-research/novo-nordisk-fy-results-results-in-line-weak-guidance",{"id":95,"title":96,"source":97,"logo":28,"time":98},355328,"Novo Nordisk Posts Strong 2025 Growth but Warns of 2026 Pricing Hit as Wegovy Pill Launches in US","https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/26146/novo-nordisk-posts-strong-2025-growth-but-warns-of-2026-pricing-hit-as-wegovy-pill-launches-in-us/","12小时前",{"id":100,"title":101,"source":102,"logo":16,"time":98},355329,"Novo Nordisk shares dive as price war hits weight-loss market","https://www.thetimes.com/business/companies-markets/article/novo-nordisk-shares-plunge-wegovy-maker-profit-warning-vzjhpkb6z?gaa_at=eafs&gaa_n=AWEtsqdLNnOxN_jM60VnDmT5YhOtcAreNFqUknvTKQpvYLXCH2N-JxyiPvhO&gaa_ts=6983aa22&gaa_sig=6ZgR_lDGRuBHlsWWLHHRN3gPfVyfXMsNYPfEhjIwwPzuFqu7H7rkpzvXXVuw9LFSapojOprYLW8Q4jISbBWMvA%3D%3D",{"id":104,"title":105,"source":106,"logo":26,"time":76},356219,"Here's the Incredible Rise and Fall of Novo Nordisk's Stock","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-04-2026/card/here-s-the-incredible-rise-and-fall-of-novo-nordisk-s-stock-736YwbMeGKvX4wIukdod?gaa_at=eafs&gaa_n=AWEtsqc2EwaQnSAi3tShqSLJ6A_H3WqfZPLEk_nIsQ5MorpHa-E-Ot_hZ2ez&gaa_ts=6983e2fc&gaa_sig=14RhbqU0NaG1pwxOIP5ZmMZF3j1_b_c3-YyBy0cWTm_SQIJqHac9GPRKzw2ueZ6YU1CMSz2hREfZiOSDmySNBw%3D%3D",{"id":108,"title":109,"source":110,"logo":5,"time":111},354974,"Novo CEO bats away talks of a crisis","https://firstwordpharma.com/story/7091490","14小时前",{"id":113,"title":114,"source":115,"logo":5,"time":116},355326,"Novo Nordisk CEO: 2026 is the year we will see a headwind for pricing in the U.S. including from 'most favored nation' policy","https://www.marketscreener.com/news/novo-nordisk-ceo-2026-is-the-year-we-will-see-a-headwind-for-pricing-in-the-u-s-including-from-mo-ce7e5adad98cfe26","22小时前",{"id":118,"title":119,"source":120,"logo":17,"time":121},356218,"NVO Stock Today: February 04 — Shares Plunge on 2026 Sales Cut","https://meyka.com/blog/nvo-stock-today-february-04-shares-plunge-on-2026-sales-cut-0402-2/","7小时前",{"id":123,"title":124,"source":125,"logo":5,"time":111},354975,"Novo Chief asks for investors’ patience as shares plunge","https://www.detroitnews.com/story/business/2026/02/04/novo-chief-asks-for-investors-patience-as-shares-plunge/88508549007/",{"id":127,"title":128,"source":129,"logo":31,"time":71},355327,"Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook","https://www.pharmexec.com/view/novo-nordisk-2025-financial-report-2026-sales-operations-profit-outlook",{"id":131,"title":132,"source":133,"logo":27,"time":134},356217,"Dow Jones Top Company Headlines at 7 AM ET: Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints | GE ...","https://news.futunn.com/en/post/68417005/dow-jones-top-company-headlines-at-7-am-et-wegovy","17小时前",{"id":136,"title":88,"source":137,"logo":32,"time":111},357306,"https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-04-2026/card/eli-lilly-vs-novo-nordisk-fortunes-diverge-for-the-weight-loss-drug-titans-BT2vph3rIvQ9vMSRBBfJ?gaa_at=eafs&gaa_n=AWEtsqf8cnD4HMRewO2HVTQyZ_BUCo2njMcACE_3cWUpD13hL3T6zdyAC9TT&gaa_ts=69841b41&gaa_sig=Nhyw8vwfpHYtmTANS-5TsOYoLw_zNgKhn2ehdb90cZ0YuYmNASXZEGjJhYUx1WvA6qZuBODzE9tE_YZU3dcgIw%3D%3D",{"id":139,"title":140,"source":141,"logo":5,"time":142},355331,"Novo Nordisk's Strategic Gamble: Navigating the Obesity Drug Price Wars","https://www.devdiscourse.com/article/business/3793677-novo-nordisks-strategic-gamble-navigating-the-obesity-drug-price-wars","15小时前",{"id":144,"title":145,"source":146,"logo":23,"time":147},356223,"Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock?","https://finviz.com/news/300085/novo-nordisk-plunges-after-releasing-a-brutal-forecast-should-you-dump-the-stock","10小时前",{"id":149,"title":150,"source":151,"logo":29,"time":152},355332,"Doustdar on poor 2026 outlook: \"We don't want to disappoint ourselves or the market\"","https://medwatch.com/News/Pharma___Biotech/article18987933.ece","16小时前",{"id":154,"title":83,"source":155,"logo":15,"time":85},356222,"https://www.wsj.com/health/pharma/wegovy-maker-novo-nordisks-shares-slump-after-guidance-disappoints-d875f651?gaa_at=eafs&gaa_n=AWEtsqe__oooRPYF2T1MHAScq_Q_vRGnBlMhgsmJGMrccU72nA3Ut_OSrBCe&gaa_ts=6983e2fc&gaa_sig=yaFaakGcbHeYgIIbDaxGja7BVPkdgRiWYLZu7IzS5_G10UqOWg9j94IVeF-OQd2On6Gq699eQu41La0L6XtRBQ%3D%3D",{"id":157,"title":158,"source":159,"logo":33,"time":160},356221,"Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank","https://www.aol.com/articles/eli-lilly-dominating-glp-1-193937051.html","9小时前",{"id":162,"title":163,"source":164,"logo":38,"time":142},355330,"Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead","https://uk.finance.yahoo.com/news/novo-nordisk-shares-plunge-outlook-152752852.html",{"id":166,"title":167,"source":168,"logo":5,"time":160},356220,"Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions","https://www.investopedia.com/eli-lilly-stock-soars-while-novo-nordisk-sinks-why-the-weight-loss-leaders-are-headed-in-opposite-directions-11899196",{"id":170,"title":145,"source":171,"logo":24,"time":147},354969,"https://www.fool.com/investing/2026/02/04/novo-nordisk-plunges-forecast-stock-nvo/",{"id":173,"title":174,"source":175,"logo":12,"time":121},356949,"Eil Lilly shares jump on strong GLP-1 sales, as Novo Nordisk tumbles","https://www.semafor.com/article/02/04/2026/eil-lilly-shares-jump-on-strong-sales-reports-as-novo-nordisk-tumbles",{"id":177,"title":178,"source":179,"logo":21,"time":98},356227,"Novo Takes Gloomy Approach To Cut Weight Of Expectations","https://insights.citeline.com/scrip/business/strategy/novo-takes-gloomy-approach-to-cut-weight-of-expectations-EPXILOSYONCILLMYQR4Z2CAF5Q/",{"id":181,"title":182,"source":183,"logo":30,"time":98},356226,"Novo Nordisk is the biggest loser in the weight-loss duopoly","https://www.ft.com/content/6d0d6699-d25b-49ca-ada0-e4af6645c403",{"id":185,"title":186,"source":187,"logo":10,"time":152},355333,"Eli Lilly leaves Novo Nordisk in the dust in weight loss drug race","https://qz.com/weight-loss-drugs-eli-lilly-novo-nordisk-earnings-stock",{"id":189,"title":190,"source":191,"logo":37,"time":147},356225,"Novo and Lilly agree prices are falling — and disagree on what comes next","https://sherwood.news/markets/novo-and-lilly-agree-prices-are-falling-and-disagree-on-what-comes-next/",{"id":193,"title":194,"source":195,"logo":19,"time":147},356224,"Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026","https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html",{"id":197,"title":198,"source":199,"logo":14,"time":76},354966,"Novo Nordisk’s falling knife is still gathering speed","https://www.breakingviews.com/columns/breaking-view/novo-nordisks-falling-knife-is-still-gathering-speed-2026-02-04/",{"id":201,"title":202,"source":203,"logo":22,"time":134},354963,"Wegovy-maker Novo Nordisk warns ’unprecedented’ price pressure to hit sales By Reuters","https://www.investing.com/news/stock-market-news/novo-nordisks-shock-2026-guidance-points-to-obesity-battle-heating-up-4483651",{"id":205,"title":206,"source":207,"logo":13,"time":208},356228,"Novo Nordisk Stock Extends Losses as Ozempic Maker Sees Sales Falling in 2026","https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-e4dd7f15?gaa_at=eafs&gaa_n=AWEtsqcUCSZhdRV2qf4Wq2hQ7DfKr9tBmIgbvOLzhTHNjt8bvdV8VQjCXRcp&gaa_ts=6983e2fc&gaa_sig=WSX64rRKX0weMA8YcwXbjIYZnTdykJdLHSgu7VaCQVNUs1rnZWjDCgEo2v3pQSP0GNVApw3PDrajAdfFnNjJcQ%3D%3D","13小时前",{"id":210,"title":211,"source":212,"logo":25,"time":142},354073,"NOVO_B: Sales grew 6% to DKK 309bn, but 2026 guidance signals a decline amid pricing and patent headwinds","https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2746741:0-novo_b-sales-grew-6-to-dkk-309bn-but-2026-guidance-signals-a-decline-amid-pricing-and-patent-headwinds/",{"id":214,"title":206,"source":215,"logo":13,"time":208},357142,"https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-e4dd7f15?gaa_at=eafs&gaa_n=AWEtsqc9SmwjQW9zdspx9U0A3-dV_xm8mq6qUFlMOmnaXURjOuLelnspaSHS&gaa_ts=69841b41&gaa_sig=x74DYmRFc9PJvjQL4zxm4nZ_cmeU5UEISPXLSiy26zE3idMDvIsqdx0Pine4QHd8piSZCzouM5paFVTyu1c4yQ%3D%3D",{"id":217,"title":83,"source":218,"logo":15,"time":85},357141,"https://www.wsj.com/health/pharma/wegovy-maker-novo-nordisks-shares-slump-after-guidance-disappoints-d875f651?gaa_at=eafs&gaa_n=AWEtsqf0RBaVqLtPT8WRbXtf2RGV8ikAiJWEHLO9xaLZhJgsVKt0_Kx3asfu&gaa_ts=69841b41&gaa_sig=rqwlG6iCgDqSADX2KlowmrjV5nsjv3rCWyySU8hH1ffmclZBS1U5WiIpJccmNhLdRmvxGX0VSggRvwGPKYp3oA%3D%3D",{"id":220,"title":221,"source":222,"logo":35,"time":223},354072,"Novo Nordisk sinks after 2026 sales outlook underwhelms","https://firstwordpharma.com/story/7091172","1天前",{"id":225,"title":105,"source":226,"logo":26,"time":76},355321,"https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-04-2026/card/here-s-the-incredible-rise-and-fall-of-novo-nordisk-s-stock-736YwbMeGKvX4wIukdod?gaa_at=eafs&gaa_n=AWEtsqdsS1Opn7O6GW6g0194BAg2CohQF5aHl45d8C-1RMz2mCYCKTNawSA6&gaa_ts=6983aa22&gaa_sig=6jKSqIAovbRzaCYI997q876S2ySP2Fe_gRPDkUjiOFoL4tjj55dP51DyD-AYXuROWj6OM7oreyDeYGPgbyGm3w%3D%3D",{"id":228,"title":229,"source":230,"logo":36,"time":142},354075,"Novo Nordisk risks weight-loss price war as discount pressures deepen","https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-risks-weight-loss-price-war-discount-pressures-deepen-2026-02-04/",{"id":232,"title":233,"source":234,"logo":34,"time":134},354076,"Novo Nordisk Warns of First Sales Drop Since Start of Ozempic","https://www.nytimes.com/2026/02/04/business/novo-nordisk-wegovy-sales-earnings.html",{"id":236,"title":88,"source":237,"logo":26,"time":111},356253,"https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-04-2026/card/eli-lilly-vs-novo-nordisk-fortunes-diverge-for-the-weight-loss-drug-titans-BT2vph3rIvQ9vMSRBBfJ?gaa_at=eafs&gaa_n=AWEtsqdbdmfbeOTpKi_92R2CnTNXSWl_ZSssb6PyHua7KPzu-i0OhvxdOCaZ&gaa_ts=6983e2fc&gaa_sig=Bm34ew6hc339n0a7p7UuLZapzJz6nP9WFESx396YXxbXllNMjLZVG9LsUC2-CMURYYcBP04xvqCOw-m5eufMlA%3D%3D",{"id":239,"title":240,"source":241,"logo":18,"time":242},354070,"Wegovy maker warns of 'painful' price cuts as shares plunge","https://www.bbc.com/news/articles/c8e5zzrjllgo","18小时前","#2c8cbeff","#2c8cbe4d",1770291075213]